

UCSF

UC San Francisco Previously Published Works

Title

Editorial Commentary: Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis

Permalink

<https://escholarship.org/uc/item/7hb2n8f2>

Journal

Clinical Infectious Diseases, 61(10)

ISSN

1058-4838

Authors

Koester, Kimberly A
Grant, Robert M

Publication Date

2015-11-15

DOI

10.1093/cid/civ783

Peer reviewed

Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis

Kimberly A. Koester¹ and Robert M. Grant^{1,2,3}

¹University of California, ²Gladstone Institutes, and ³San Francisco AIDS Foundation, California

(See the Brief Report HIV/AIDS by Volk et al on pages 1601–3.)

Keywords. HIV pre-exposure prophylaxis; HIV prevention; pre-exposure prophylaxis.

Biomedical approaches to preventing human immunodeficiency virus (HIV) have advanced quickly, particularly over the last 5 years. A significant milestone occurred in July 2012 when the U.S. Food and Drug Administration (FDA) approved the use of daily oral emtricitabine/tenofovir disoproxil fumarate (Truvada) as HIV pre-exposure prophylaxis (PrEP). Many questions remain: What proportion of the population vulnerable to HIV will take a pill a day to prevent it? How will the costs of the medication and clinic visits be paid for? Assuming people are willing to use PrEP and can access PrEP, will they take the medication as directed? Will uptake and use be higher or lower among those at highest risk? Will people place themselves at higher risk for HIV and sexually transmitted infections (STIs) as a consequence of using PrEP?

We are slowly accumulating answers to these key questions. The study by Volk and colleagues in this issue sheds light on issues related to PrEP uptake, access, and adherence [1]. PrEP uptake has been characterized as “slow” [2–4], although it is not clear what is used as a reference point. Disseminations of successful innovations often require many years, as occurred with hormonal contraception, hepatitis B and human papilloma virus vaccination, and combination antiretroviral therapy for HIV infection. Volk et al’s graphical comparison of referrals, intakes, and initiation among patients seen in a primary care facility illustrates a dramatic increase in uptake approximately 1 year after FDA approval. This striking uptake produced an expected and most desired outcome—no new HIV infections—among a population vulnerable to HIV. Given the historical devastation wrought by HIV/AIDS within the city of San Francisco and elsewhere, this is tremendously good news. Despite intensive efforts to curb HIV transmission, San Francisco data from 2013 indicate that approximately 1 HIV infection occurs each day [5]. San Francisco is actively working towards the United Nations AIDS Getting to Zero goal to halt all new HIV infections, HIV-related deaths, and HIV-related stigma. The data published by Volk and colleagues demonstrate meaningful progress toward the goal of halting new infections.

What insights can we draw from the results so well reported on by Volk and colleagues? First, we want to highlight and commend the authors working within the Kaiser system for creating a clinical environment conducive for gay men and other men who have sex with men to feel comfortable enough to use their specialized PrEP program. In an ethnographic study performed in San Francisco, we found that many men who have sex with men seek sexual health services, including PrEP, outside of primary care in municipal- or community-based clinics [6]. Such clinics made it easier to be seen in a timely fashion, and men appreciated the higher quality sexual health screening and counseling they received. In addition, due to the stigma that persists regarding gay men’s sexual activities and the shame some have experienced, many participants preferred to separate sexual health care from their ongoing primary care relationship. Volk and colleagues’ experience provides evidence that men will seek or accept PrEP in the context of a specialized program situated within a primary care setting. Providing PrEP services within primary care practices also occurs, although the acceptability and feasibility of such integration remains to be demonstrated.

Second, it is not clear from the Volk et al article whether the reported rate of

Received 4 August 2015; accepted 7 August 2015; electronically published 1 September 2015.

Correspondence: Kimberly A. Koester, MA, Center for AIDS Prevention Studies, UCSF, 550 16th St, 3rd Flr, San Francisco, CA 94158-2549 (kimberly.koester@ucsf.edu).

Clinical Infectious Diseases® 2015;61(10):1604–5

© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

DOI: 10.1093/cid/civ783

sexually transmitted infections is an increase over and above a baseline level or not. Men who seek PrEP services tend to report more numbers of sexual partners and less condom use, so STIs are commonly present when PrEP is initiated [7]. Testing for and management of STIs when starting PrEP should be the standard of care. The increased frequency of STI testing offered during PrEP services affords more timely diagnosis and treatment of STIs, and high rates of diagnosis may reflect greater diagnostic yield rather than changes in sexual behavior. Furthermore, men who commonly sought sexual health services outside the Kaiser Permanente system in convenient community-based clinics are now being tested within the Kaiser Permanente PrEP services. What appears to be high rates of STI diagnosis may reflect appropriate use of PrEP by people who have the most to benefit and people staying closer to their medical home for sexual health services.

It is time for a vigorous conversation about STIs, too long eclipsed by fear of HIV infection. The conversation should include public health officers, clinicians, clients, and sexual partners. Routine STI testing within primary care practices is often not performed, representing a missed opportunity for epidemic control and an expansion of the scope of primary care to continually include sexual health. Although HIV testing and trends are frequently in the news, notice of STI trends remain unnoticed in technical reports. People and prospective partners frequently exchange information about HIV test results, HIV treatment outcomes, and adherence, whereas discussion of other STIs is left for the morning after or after the appearance of

symptoms of infection. Feeling safer from HIV infection while using PrEP [8] creates space for a more robust discussion of STIs.

The U.S. Centers for Disease Control and Prevention PrEP guidelines encourage STI testing at least every 6 months. PrEP is best combined with a parallel plan to prevent other STIs, which may include use of condoms, frequent testing and treatment, and discussion of STI test results with prospective partners. We may also consider promoting STI self-testing and self-treatment. Trusting that PrEP users and their communities will respond to the threat of STIs can allow for novel and potentially more durable transformation of sexual health-promoting behaviors. For example, members of the gay community historically led the innovations around safer sex practices in the face of HIV/AIDS [9]. If the STI burden in the context of PrEP use become too great, communities can and will make course corrections. Finally, in a report in *Clinical Infectious Diseases* in 2014, McCormack and colleagues pointed out that the resurgence of STIs among men who have sex with men predates the advent of PrEP [10]. Sexual practices and the social life of condoms are in flux; they were before PrEP, and they will continue to be. Ideally, the public health response to the possibility of rising incidence of STIs in the context of decreased or no new HIV infections would be framed in relative terms and therefore considered to be a good problem to have.

Note

Potential conflict of interest. Both authors: No reported conflicts.

Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. *Clin Infect Dis* **2015**; 61:1601–3.
2. Siemieniuk RAC, Sivachandran N, Murphy P, et al. Transitioning to HIV pre-exposure prophylaxis (PrEP) from non-occupational post-exposure prophylaxis (nPEP) in a comprehensive HIV prevention clinic: a prospective cohort study. *AIDS Patient Care STDs* **2015**; 29:431–6.
3. Kirby T, Thornber-Dunwell M. Uptake of PrEP for HIV slow among MSM. *Lancet* **2014**; 383:399–400.
4. Burns DN, Grossman C, Turpin J, et al. Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies. *Curr HIV/AIDS Rep* **2014**; 11:393–403.
5. HIV Epidemiology Section, San Francisco Department of Public Health. HIV epidemiology annual report. San Francisco, CA: San Francisco Department of Public Health, **2013**. Available at: <https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/HIVAIDAnnRpt2013.pdf>. Accessed 5 July 2015.
6. Koester KA, Collins SP, Fuller SM, et al. Sexual healthcare preferences among gay and bisexual men: a qualitative study in San Francisco, California. *PLoS One* **2013**; 8:e71546.
7. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. *Lancet Infect Dis* **2014**; 14:820–9.
8. Koester KA, Amico R, Liu A, et al. Sex on PrEP: qualitative findings from the iPrEx open label extension (iPrEx OLE) in the US [abstract TUAC0102]. In: Program and abstracts of the 20th International AIDS Conference (Melbourne). Geneva, Switzerland: International AIDS Society, **2014**.
9. Berkowitz R. *Stayin' alive: the invention of safe sex*. Boulder: Westview Press, **2003**.
10. McCormack SM, Gafos M, Desai M, Cohen MS. Biomedical prevention: state of the science. *Clin Infect Dis* **2014**; 59(suppl 1): S41–6.